Charlie's Q3 Revenue Falls 56% to $2.7M; Cash Drops to $356K
CHUC has more than doubled off its 52-week low of $0.013 on light trading volume (0.2× avg).
Summary
Charlie's Q3 revenue dropped 56% to $2.7M and gross profit fell to $136K, leaving $356K of cash and a $4.5M nine-month net loss. The main offsetting development is the FDA's November 18 rescission of three PMTA denial letters.
Key Events · Earnings and Guidance · CHUC
-
Q3 Revenue Falls 56%
Product revenue was $2,704,000 versus $6,132,000 a year earlier, a 55.9% decline driven primarily by a significant decrease in SBX product line sales.
-
Gross Margin Collapses to 5%
Gross profit fell 91.6% to $136,000 from $1,625,000 after the company sold aging inventory at or near cost to a single large customer, sales it says are outside the normal course and not expected to recur.
-
Cash Down to $356,000
Cash fell from $1,320,000 at December 31, 2025 to $356,000, and working capital dropped to $1,022,000 from $3,137,000; nine-month operating cash use was $2,428,000.
-
Receivables Financing Adds Costly Debt
The July 23, 2026 Austin Business Finance agreement provided $1,000,000 net of a 1% origination fee but requires 52 weekly payments of $24,615 totaling $1,280,000; $851,000 remained outstanding at quarter end.
Analysis · CHUC · Life Sciences
The headline is a sharp deterioration in the core business: revenue fell 55.9% to $2.7M in Q3 as SBX sales collapsed, and gross profit nearly vanished at $136K after the company sold aging inventory at or near cost to one large customer. For the nine months, the picture is a $4.5M net loss against $4.4M of net income a year ago, which was propped up by a one-time $7.5M PMTA asset sale gain. Cash is down to $356K from $1.3M at year-end, and the company is leaning on a $1.0M receivables sale that must be repaid with $1.28M over 52 weeks. Management says it is funded for twelve months, but that depends on further PMTA asset sales or partnerships. The one clear positive is regulatory: on November 18, 2026 the FDA rescinded three denial letters and put those PMTAs back into review, and the Fifth Circuit is briefing the remaining appeal with an FDA response due November 30, 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHUC was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $0.01 to $0.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.